InflaRx Unveils New Developments for INF904
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company recognized for its innovative anti-inflammatory therapies targeting the complement system, has recently shared promising preclinical results for its oral C5aR inhibitor, INF904. This announcement took place at the 2024 European Meeting on Complement in Human Diseases (EMCHD) in Lübeck, Germany, where experts from the industry convened to discuss the latest advancements in inflammation research.
Active Participation at EMCHD
InflaRx's leadership team engaged actively in a satellite symposium, focusing on the crucial role of the C5a/C5aR1 axis in the inflammation process. They also contributed to discussions regarding the significance of targeting C3 and C5 in strategies for treating inflammation. Additionally, the company organized a lunch seminar that offered valuable insights into C5a/C5aR inhibition and its potential applications in human health.
Insights from the Chief Medical Officer
Dr. Camilla Chong, Chief Medical Officer of InflaRx, expressed her excitement about the preclinical data shared at EMCHD 2024. She remarked, “We are thrilled to showcase our dedication to advancing the science of complement inhibition. The findings underscore our ambition to develop leading anti-inflammatory therapies through C5a and C5aR inhibition.” This preclinical evidence highlights the significant anti-inflammatory potential and strong pharmacokinetic properties of INF904.
Exploring INF904's Mechanism
The study characterized INF904 as a highly selective and potent inhibitor of C5aR1, demonstrating impressive pharmacokinetic (PK) attributes. In controlled experiments, INF904 achieved an outstanding 96.5% inhibition of C5a-induced neutropenia, surpassing avacopan, which recorded a 51.1% inhibition at the same dosage. Furthermore, INF904's PK profile was significantly better, showing 2- to 5-fold higher drug exposure across various animal models compared to avacopan, suggesting a promising therapeutic future.
Pharmacological Profile of INF904
The results further indicated that INF904 exhibits a much weaker inhibition of CYP3A4/5 enzymes, which are essential for metabolizing many medications, including glucocorticoids. This characteristic implies that INF904 may provide a safer alternative regarding drug interactions, which is particularly important for patients on multiple therapies.
INF904's Potential in Treating Inflammatory Diseases
INF904 stands out not only as a groundbreaking C5a receptor antagonist but also demonstrates encouraging effects across various inflammatory disease models. Results from both in vitro and in vivo studies show that INF904 effectively reduces neutrophil activation, a major contributor to inflammation. In whole blood disease models and hamster models, the compound significantly decreased neutrophil influx and improved relevant biochemical markers, highlighting its therapeutic potential.
Demonstrated Therapeutic Effects
Clinical observations have indicated that INF904 leads to notable improvements in metabolic markers such as CREA and BUN levels. These therapeutic effects underscore the extensive potential of INF904 as an anti-inflammatory treatment, aligning with ongoing efforts to develop advanced therapies for conditions characterized by excessive inflammation.
About InflaRx: Commitment to Innovation
Founded in 2007, InflaRx is dedicated to discovering and developing effective anti-inflammatory agents by utilizing its proprietary technologies. Its leading product candidate, vilobelimab, has already shown clinical efficacy and has garnered attention in various studies. InflaRx continues to advance its research initiatives, including the further development of INF904, which is positioned as a pioneering oral treatment option.
Contact Information
For more information, please reach out to InflaRx N.V. or its partner MC Services AG using the following:
InflaRx N.V.
Jan Medina, CFA
Vice President, Head of Investor Relations
Email: IR@inflarx.de
MC Services AG
Katja Arnold, Laurie Doyle, Dr. Regina Lutz
Email: inflarx@mc-services.eu
Europe: +49 89-210 2280
U.S.: +1-339-832-0752
Frequently Asked Questions
What is INF904?
INF904 is an orally administered small molecule that acts as a C5a receptor antagonist, showing promise in reducing inflammation.
How was INF904 evaluated?
INF904's effects were assessed through various preclinical models, including in vivo assessments and cell-based assays.
What sets INF904 apart from other treatments?
Its selective inhibition of C5aR1 and minimal impact on crucial metabolic enzymes such as CYP3A4/5 suggest lower potential for drug interactions.
What are the anticipated benefits of INF904?
The findings indicate strong anti-inflammatory effects, particularly in neutrophil-driven inflammatory responses, making it a hopeful candidate for further clinical exploration.
How does InflaRx plan to progress with INF904?
InflaRx is committed to advancing INF904 through continued research and development, aiming for clinical applications in inflammatory diseases.
